# Rifaximin to Prevent Recurrent HCV-Related Fibrosis After Liver Transplant

> **NCT01603108** · PHASE2 · UNKNOWN · sponsor: **Columbia University** · enrollment: 59 (actual)

## Conditions studied

- Hepatitis C

## Interventions

- **DRUG:** Rifaximin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01603108
- **Lead sponsor:** Columbia University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2012-03
- **Primary completion:** 2016-12
- **Final completion:** 2018-12
- **Target enrollment:** 59 (ACTUAL)
- **Last updated:** 2016-04-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01603108

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01603108, "Rifaximin to Prevent Recurrent HCV-Related Fibrosis After Liver Transplant". Retrieved via MORVS 2026-10-12 from https://api.morvs.ai/clinical/NCT01603108. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*